Answers are grounded in this paper and cite their sources.
The cGAS-STING pathway serves as a critical innate immune sensor, yet its role in orchestrating the tumor microenvironment (TME) in melanoma (SKCM) remains controversial. Tumor-associated macrophages (TAMs) are abundant in SKCM and are key drivers of immunosuppression. However, the interplay between cGAS-STING activation in the TME and TAM polarization has not been systematically mapped. We utilized public multi-center bulk profiles of SKCM patients for identification of cGAS-STING and TAM (CT)-associated hub gene signature and overall survival (OS) stratification model for SKCM patients via various bioinformatic approaches, such as Limma, WGCNA, cox regression and integrated machine learning. Next, we also identified molecular and immune heterogeneity between CT-associated risk groups. In addition, molecular and immune patterns of CT-associated hub gene signature in TAM were assessed in SKCM patient single-cell level via various cutting-edge single-cell analytical frameworks at spatial and temporal manners. Drug sensitivity and deep learning-based drug screening were performed to identify potential drug repurposing approaches based on GDSC database and natural therapeutic candidates based on the ingredient of (FuFang KuShen, FFKS) targeting CT-associated hub gene for SKCM patients. Finally, in vitro assays validated the major findings of our study. We identified a CT-associated gene signature that effectively stratified SKCM patients into distinct risk groups with divergent immune landscapes, and nominated IL6, CXCL10 and ICAM1 as CT-associated and TAM-specific hub genes in SKCM progression. Furthermore, Tivantinib, NSC48300, Saracatinib can be considered as reproposing approaches targeting CT-associated hub gene in the treatment of SKCM. Novelty, Ingredient in FFKS (Matrine) can be considered as potential natural compound in the treatment of SKCM. Our study decodes the CT-associated molecular patterns in SKCM, highlighting TAM-specific hub genes as key mediators of tumor progression and offering a promising therapeutic avenue for precision oncology.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: